Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This guide compares risk levels between bonds and stocks in retirement, outlining factors like market cycles, duration, and income needs.
28,627 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
When homes linger on the market, buyers gain negotiating power and lenders adjust terms. This guide explains how stal...
MBA Chief Bob Broeksmit calls for relief from cost-adding rules as mortgage rates remain elevated, urging targeted re...
A Nashville case highlights a troubling form of elder financial exploitation. Learn how scams work, the signs to watc...
Ripple secures full authorization under MiCA from Luxembourg's CSSF, enabling its XRP-based payments platform to oper...
Gold’s flagship ETF saw a record-size outflow as crypto-linked funds posted weekly gains. The week ended with mixed s...
Investors bias portfolios by political leanings, potentially hurting gains. Experts say open dialogue across camps ca...
SpaceX stock has retraced from its post-IPO highs, leaving questions about future gains. This guide breaks down why t...
A major share sale spooked investors and pushed Brightstar Lottery stock down. This guide breaks down what happened, ...
Five former Binance investigators allege the exchange processed nearly $1B in Iran sanctions–related transactions aft...
United Airlines faces near term pressure from higher fuel costs, yet the Street remains optimistic with a consensus t...
BTSE Bhutan has secured an In-Principle Approval from Gelephu regulators to build a regulated crypto trading and cust...